Coughlin Timothy 4

What Happened
Timothy Coughlin, a director of Vir Biotechnology, received equity awards on June 9, 2026 totaling 48,000 shares at a $0.00 acquisition price. The filing shows two non-derivative awards of 8,000 shares each (16,000 RSUs total) and two derivative awards of 16,000 shares each (32,000 stock-option type awards), all reported as grants/awards rather than purchases or sales. No cash was exchanged; these are compensatory awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (timely filing).
• Price: $0.00 per share (awarded).
• Total awarded: 48,000 shares (16,000 RSUs; 32,000 derivative awards/stock options as reported).
• Shares owned after transaction: Not disclosed in this Form 4.
• Notable footnotes:
  • RSUs granted pursuant to the issuer’s Equity Incentive Plan (vesting: 1/3 on June 9, 2027, remainder in two equal annual installments; in some RSU awards vest in full on earlier of June 9, 2027 or next annual meeting).
  • Stock-option-type awards vesting: 1/3 on June 9, 2027 with remaining shares vesting in 24 equal monthly installments; in some awards vest in full on earlier of June 9, 2027 or next annual meeting.
• Filing status: Appears timely (filed next day).

Context

• RSUs are restricted stock units that convert to shares as they vest; stock-option-type awards are derivative grants that become exercisable according to the vesting schedules above.
• These awards are compensatory (routine director/employment equity) and do not indicate an immediate buy or sell of stock.
• No indication in the filing that shares were sold or that a cashless exercise occurred.